FDA Moves to Allow Over a Do Previously Banned Peptides
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- FDA is moving toward allowing compounding pharmacies to produce over a dozen injectable peptides that were previously banned for safety risks.
- FDA removed 14 peptides from the list of products it permits compounding pharmacies to produce in 2023.
- FDA noted that the unapproved peptides were marketed with unproven claims of cosmetic, anti‑aging, and disease‑fighting benefits.
- Robert F. Kennedy Jr. is pushing the FDA to reverse the prohibition on the peptides, including some that act as growth‑hormone stimulators.
- Kennedy said on Joe Rogan’s podcast that he personally used the peptide products to heal injuries with "really good effect."
Why it matters: Compounding pharmacies will be able to manufacture over a dozen previously banned injectable peptides, expanding their product lines while the FDA eases safety safeguards; patients will receive peptides marketed with unproven anti‑aging and disease‑fighting claims, reshaping the off‑label peptide market.
